Get the Stockscreener App
1.02
3.32%
-0.035
After Hours:
1.01
-0.01
-0.98%
BiomX Inc stock is traded at $1.02, with a volume of 31,715.
It is down -3.32% in the last 24 hours and down -16.39% over the past month.
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
See More
Previous Close:
$1.055
Open:
$1.05
24h Volume:
31,715
Relative Volume:
0.58
Market Cap:
$18.25M
Revenue:
-
Net Income/Loss:
$-26.56M
P/E Ratio:
-1.36
EPS:
-0.75
Net Cash Flow:
$-22.29M
1W Performance:
-6.42%
1M Performance:
-16.39%
6M Performance:
-77.33%
1Y Performance:
-71.02%
1-Day Range:
$1.015
$1.09
1-Week Range:
$1.015
$1.15
52-Week Range:
$0.94
$8.55
BiomX Inc Stock (PHGE) Company Profile
Name
BiomX Inc
Sector
Industry
Phone
972 7 23942377
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-21 | Initiated | Ladenburg Thalmann | Buy |
BiomX Inc Stock (PHGE) Latest News
BiomX Shares Phage Therapy Advances and Vision - TipRanks
Bacteriophages Therapy Market Size, Share And Growth Analysis - openPR
BiomX Stock Gains From Favorable Study Data Presentation on BX004 - Yahoo Finance
BiomX to present data from Phase 1b/2a study of BX004 - TipRanks
BiomX to Provide Latest Update on Positive Phase 1b/2a - GlobeNewswire
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference - StockTitan
Biomx stock plunges to 52-week low, hits $1.05 - Investing.com
Biomx stock plunges to 52-week low, hits $1.05 - Investing.com India
BiomX (NYSEMKT:PHGE) Trading Down 5.4% - MarketBeat
BiomX (NYSEMKT:PHGE) Shares Down 5.4% - Defense World
Bacteriophage Therapy Market Projected To Witness Substantial Growth, 2024-2031: Enbiotix, Inc., Nextbiotics, - EIN News
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
PHGEBiomX Inc. Latest Stock News & Market Updates - StockTitan
Biomx stock plunges to 52-week low at $1.15 amid market challenges - Investing.com
BiomX to Present Positive Phase 1b/2a Clinical Trial Data - GlobeNewswire
Biomx stock plunges to 52-week low at $1.15 amid market challenges - Investing.com UK
BiomX to present cinical trial data for BX004 at ERS - TipRanks
BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024 - StockTitan
Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Drops By 92.9% - MarketBeat
BiomX Inc (PHGE) stock analysis: A comprehensive overview - US Post News
Biomx stock plunges to 52-week low at $0.14 amid market challenges - Investing.com
Biomx stock plunges to 52-week low at $0.14 amid market challenges - Investing.com Australia
Biomx stock plunges to 52-week low at $0.14 amid market challenges - Investing.com UK
There is no doubt that BiomX Inc (PHGE) ticks all the boxes. - SETE News
PHGE’s 2023 Market Dance: Down -44.29% – Time to Invest? - The InvestChronicle
Balance Sheet Insights: BiomX Inc (PHGE)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
BiomX Inc (PHGE)’s highs and lows: A closer look at its stock price fluctuations - US Post News
BiomX (PHGE) Cash Flow from Discontinued Operations : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
BiomX (PHGE) 14-Day RSI : 28.12 (As of Aug. 18, 2024) - GuruFocus.com
BiomX (NYSEMKT:PHGE) Rating Reiterated by HC Wainwright - Defense World
BiomX (NYSEMKT:PHGE) Shares Scheduled to Reverse Split on Monday, August 26th - Defense World
BiomX announces reverse stock split effective August 26 By Investing.com - Investing.com Australia
BiomX announces reverse stock split effective August 26 By Investing.com - Investing.com UK
BiomX shares maintain $2 target with Buy rating by H.C. Wainwright - Investing.com Canada
BiomX announces 1-for-10 reverse stock split - TipRanks
UPDATE ON UNITSBiomX Inc. Announces 1-for-10 Reverse Stock Split - GlobeNewswire
UPDATE ON UNITSBiomX Inc. Announces 1-for-10 Reverse Stock Split - StockTitan
Earnings call: BiomX reports Q2 2024 financials, clinical updates By Investing.com - Investing.com Australia
Earnings call: BiomX reports Q2 2024 financials, clinical updates - Investing.com
Earnings call: BiomX reports Q2 2024 financials, clinical updates By Investing.com - Investing.com UK
BiomX Inc. (AMEX:PHGE) Q2 2024 Earnings Call Transcript - Insider Monkey
BiomX Inc Inc. (PHGE) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Daily Progress: BiomX Inc (PHGE) Drop -11.58, Closing at 0.16 - The Dwinnex
Biomx stock plunges to 52-week low, hitting $0.17 - Investing.com
Biomx stock plunges to 52-week low, hitting $0.17 By Investing.com - Investing.com UK
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates - GlobeNewswire
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates - wallstreet:online
BiomX Inc. Announces 1-for-10 Reverse Stock Split - GlobeNewswire
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates - The Bakersfield Californian
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates - StockTitan
BiomX Inc Stock (PHGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):